Home World News Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with... World News Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 690 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ESMO’s Special Consultative Status with United Nations Economic and Social Council... October 10, 2025 How and When to Wash Your Reusable Cloth Mask and When... November 30, 2020 A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival... January 25, 2022 Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 Load more HOT NEWS Health inequalities: breaking down barriers to cancer screening Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΕΟΥΣ
